Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03293030 · ClinicalTrials.gov registry record · Phase 4
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT03293030 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 17 participants.
The verdict
NCT03293030, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03293030
The ClinicalTrials.gov registry entry for NCT03293030 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03293030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03293030 about?
NCT03293030 is a clinical study titled "Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis". This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
What is the current status of trial NCT03293030?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2018-10-22. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT03293030?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03293030?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.